1 min read
Add as a preferred source on Google

Abivax Shares Fall About 9% After Scorpion Research Short Report

The report criticized the clinical development of obefazimod, Abivax’s ulcerative colitis candidate. Scorpion Research disclosed a short position in the company.

A glass vial rests beside a sharply creased share certificate / TokenPost.ai
A glass vial rests beside a sharply creased share certificate / TokenPost.ai

Abivax shares closed down about 9% Friday, Nov. 20, 2026, after Scorpion Research issued a short report criticizing the clinical development of the company’s ulcerative colitis candidate, obefazimod.

Scorpion Research disclosed that it holds a short position in Abivax. The report’s criticism was directed at obefazimod’s clinical development.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…